BRIEF published on 10/01/2024 at 00:56, 1 month 20 days ago Valerio Therapeutics publie ses résultats financiers du premier semestre 2024 Résultats Financiers R&D Essai Clinique Valerio Therapeutics Anticorps À Domaine Unique
BRIEF published on 10/01/2024 at 00:56, 1 month 20 days ago Valerio Therapeutics Reports First Half 2024 Financial Results Financial Results R&D Clinical Trial Valerio Therapeutics Single Domain Antibodies
PRESS RELEASE published on 10/01/2024 at 00:51, 1 month 20 days ago Inside Information: News release on accounts, results Valerio Therapeutics annonce ses résultats financiers du Premier Semestre 2024 et fait le point sur ses activités, y compris l'acquisition d'Emglev Therapeutics et le développement de la plateforme PlatONTM Résultats Financiers Biotechnologie Valerio Therapeutics Emglev Therapeutics Plateforme PlatONTM
BRIEF published on 10/01/2024 at 00:45, 1 month 20 days ago Valerio Therapeutics publie ses résultats financiers du premier semestre 2024 et ses mises à jour stratégiques Résultats Financiers Plateforme PlatONTM Acquisition D'Emglev Essai Clinique VIO-01 Innovations Thérapeutiques
BRIEF published on 10/01/2024 at 00:45, 1 month 20 days ago Valerio Therapeutics Reports Half-Year 2024 Financial Results and Strategic Updates Financial Results Emglev Acquisition VIO-01 Clinical Trial PlatON™ Platform Therapeutic Innovations
PRESS RELEASE published on 10/01/2024 at 00:40, 1 month 20 days ago Inside Information: News release on accounts, results Valerio Therapeutics reports its half-year 2024 financial results and updates on its activities, including the acquisition of Emglev Therapeutics and progress on the VIO-01 trial Acquisition Financial Results Valerio Therapeutics VIO-01 Trial Emglev Therapeutics
PRESS RELEASE published on 09/30/2024 at 22:40, 1 month 20 days ago Rapports financiers et d'audit semestriels/examens réduits / Rapport financier semestriel
PRESS RELEASE published on 09/30/2024 at 22:40, 1 month 20 days ago Half yearly financial reports and audit reports/limited reviews / Half yearly financial report
BRIEF published on 08/05/2024 at 19:23, 3 months 15 days ago Bilan semestriel du contrat de liquidité avec Kepler Cheuvreux Contrat De Liquidité Transactions Kepler Cheuvreux AMF Valerio Therapeutics
BRIEF published on 08/05/2024 at 19:23, 3 months 15 days ago Half-yearly review of the liquidity contract with Kepler Cheuvreux Liquidity Contract Transactions Kepler Cheuvreux AMF Valerio Therapeutics
Published on 11/21/2024 at 12:00, 1 hour 1 minute ago Alset AI Announces Full Repayment of $3.7 Million Secured Loan with Interest from Portfolio Company, Significantly Strengthening Balance Sheet
Published on 11/21/2024 at 12:00, 1 hour 1 minute ago Battery X Metals Commences Strategic Initiatives to Strengthen Balance Sheet
Published on 11/21/2024 at 11:30, 1 hour 31 minutes ago FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 2 hours 58 minutes ago Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 3 hours 1 minute ago BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 12:35, 26 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 46 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 11:30, 1 hour 31 minutes ago APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived
Published on 11/21/2024 at 06:58, 6 hours 3 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours 3 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours 3 minutes ago Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 16 hours 53 minutes ago Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 17 hours 41 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
